INT84890

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1999
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 7
Disease Relevance 3.27
Pain Relevance 3.10

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (PPARD) nucleoplasm (PPARD) DNA binding (PPARD)
lipid metabolic process (PPARD) cell proliferation (PPARD) lipid binding (PPARD)
Anatomy Link Frequency
cleavage 2
PNT1A 1
PPARD (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 2 100.00 Very High Very High Very High
agonist 55 99.86 Very High Very High Very High
aspirin 22 99.84 Very High Very High Very High
cINOD 33 99.38 Very High Very High Very High
dexamethasone 25 89.72 High High
Inflammation 147 88.12 High High
Thalamus 1 54.00 Quite High
Inflammatory response 10 5.00 Very Low Very Low Very Low
COX-2 inhibitor 5 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Apoptosis 25 99.48 Very High Very High Very High
INFLAMMATION 170 89.08 High High
Cancer 149 85.36 High High
Repression 1 80.40 Quite High
Colon Cancer 8 79.48 Quite High
Myocardial Infarction 3 69.28 Quite High
Reprotox - General 1 25 65.84 Quite High
Toxicity 11 64.64 Quite High
Renal Cancer 1 60.48 Quite High
Disease 36 58.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These findings suggest that NSAIDs inhibit tumorigenesis through inhibition of PPARdelta, the gene for which is normally regulated by APC.
Negative_regulation (inhibition) of PPARdelta associated with cinod
1) Confidence 0.59 Published 1999 Journal Cell Section Abstract Doc Link 10555149 Disease Relevance 0.48 Pain Relevance 0.45
Also the administered coxibs (rofecoxib 12.5 to 25 mg daily or etoricoxib 60 mg daily) may express transcriptional activity by the inhibition of PPAR-delta.
Negative_regulation (inhibition) of PPAR-delta
2) Confidence 0.29 Published 2008 Journal Cancer Microenviron Section Body Doc Link PMC2654356 Disease Relevance 0.73 Pain Relevance 0.28
Because of suppression of ectopic PPARdelta by sulindac, adenoviral PPARdelta transduction failed to restore 14-3-3epsilon or prevent PPAR cleavage.
Negative_regulation (suppression) of PPARdelta in cleavage
3) Confidence 0.19 Published 2008 Journal Mol. Pharmacol. Section Abstract Doc Link 18678619 Disease Relevance 0.50 Pain Relevance 0.49
SUL inhibited PPARdelta promoter activity, which correlated with 14-3-3epsilon promoter suppression.
Negative_regulation (inhibited) of PPARdelta
4) Confidence 0.18 Published 2008 Journal Mol. Pharmacol. Section Abstract Doc Link 18678619 Disease Relevance 0.66 Pain Relevance 0.68
SUL, IND, and ASA (5 mM) suppressed PPARdelta and 14-3-3 proteins in a manner parallel to PARP cleavage.
Negative_regulation (suppressed) of PPARdelta in cleavage associated with aspirin
5) Confidence 0.18 Published 2008 Journal Mol. Pharmacol. Section Abstract Doc Link 18678619 Disease Relevance 0.68 Pain Relevance 0.64
Peroxisome proliferator-activated receptor response element

(PPRE) is defined as a direct repeat of two core recognition

Negative_regulation (defined) of proliferator-activated receptor response element
6) Confidence 0.04 Published 2004 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC551585 Disease Relevance 0.05 Pain Relevance 0.06
In this study, we show that sulindac sulfide acts both as a PPARgamma agonist and a PPARdelta antagonist in an immortalized prostatic epithelial cell line (PNT1A).
Negative_regulation (antagonist) of PPARdelta in PNT1A associated with antagonist and agonist
7) Confidence 0.04 Published 2005 Journal Oncogene Section Abstract Doc Link 16091736 Disease Relevance 0.17 Pain Relevance 0.51

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox